Home
Search

Press Releases

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels. 

Featured Press Releases
BIO Statement on December 2025 ACIP Meeting
WASHINGTON, D.C. – Phyllis Arthur, Executive Vice President and Head of Health Policy and Programs of the Biotechnology Innovation Organization (BIO) released the following statement on the December 2025 ACIP meeting.“For decades, the CDC’s Advisory…
Learn more
BIO Statement on the Retirement of Richard Pazdur…
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on reports of the retirement of Richard Pazdur from the US FDA.“Dr. Pazdur has dedicated decades of his career…
Learn more
BIO Statement on House Passage of Mikaela Naylon…
WASHINGTON, D.C. – The Biotechnology Innovation Organization (BIO) released the following statement on today’s passage of the Mikaela Naylon Give Kids a Chance Act in the House of Representatives.“The unanimous House passage of the Mikaela Naylon…
Learn more
All Press Releases
  • Show All
Search
Results
Event Tags
BIO Asks EPA To Use a Forward-Looking Methodology in Setting Renewable Fuel Standards
August 31, 2017
BIO today submitted comments on EPA's proposed rule on the Renewable Fuel Standard Program: Standards for 2018 and Biomass-Based Diesel Volume for 2019.
BIO Statement on Nomination of Andrei Iancu to Lead U.S. Patent and Trademark Office
August 29, 2017
Washington, D.C. (August 29, 2017) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement on the nomination of Andrei Iancu to lead the U.S. Patent and Trademark Office:“BIO congratulates Mr…
BIO Applauds Signing of Food and Drug Administration Reauthorization Act (FDARA)
August 18, 2017
Enactment of FDA User Fee package important victory for patients, medical innovation
Fireside Chat Speakers, Programming Announced for 2017 BIO Investor Forum
August 15, 2017
BIO announces programming for the upcoming BIO Investor Conference Oct. 17-18 in San Francisco including Kristina Burow, Managing Director of ARCH Venture Partners and Dr. Richard Scheller, Chief Science Officer & Head of Therapeutics…
BIO: Senate Passage of FDA User Fee Package Important Victory for Patients, Medical Innovation
August 3, 2017
Washington, DC (August 3, 2017) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement regarding passage of the Food and Drug Administration Reauthorization Act (FDARA) by the U.S…
BIO Applauds US Court of Appeals Decision on the Renewable Fuel Standard
July 28, 2017
The U.S. Court of Appeals for the District of Columbia Circuit today supported BIO's argument that the RFS statute does not allow EPA to rely on demand-side factors under the oil industry’s control as a basis for setting annual renewable fuel…
The 2017 BIO World Congress Comes to a Close in Montreal
July 26, 2017
The 14th annual BIO World Congress drew 954 attendees. The world’s largest industrial biotechnology event hosted more than 227 speakers in seven education tracks and five plenaries and set a new conference record for partnering meetings.
Democrats' Plan on Drug Costs a “Bad Deal for Patients and the Future of American Innovation”
July 24, 2017
Plan will restrict seniors’ access to prescription drugs and undermine quest for biopharmaceutical innovations and curesWashington, DC (July 24, 2017) – Biotechnology Innovation Organization (BIO) Director of Communications Brian Newell…
Gord Surgeoner to Receive 2017 BIO Leadership and Legacy Award
July 18, 2017
Dr. Gord Surgeoner, OOnt, former president of Ontario Agri-Food Technologies (OAFT), will receive the 2nd annual BIO Leadership and Legacy Award on Wednesday July 26, 2017, during a lunch plenary session of the 2017 BIO World Congress on Industrial…
BIO Statement on the Status of the U.S.-China 100-Day Plan
July 17, 2017
Washington, D.C. (July 17, 2017) – The Biotechnology Innovation Organization (BIO) today issued the following statement on the status of the U.S.-China 100-day plan:
gooddaybio-cover-final
Daily News You Can’t Afford to Miss

Read it in under 3 minutes!

The Good Day BIO newsletter is the only daily newsletter at the intersection of biotech, politics, and policy. 

Sign Up Today